INTRODUCTION AND OBJECTIVES:
A recent study showed that adipose-derived stem cells are able to counteract urethral stricture formation in rats. The aim of this study was to evaluate the feasibility of autologous adipose derived stromal vascular fraction (SVF) transplantation into male urethra stricture walls after direct vision incision of urethra (DVIU).
METHODS: A prospective clinical study was undertaken after ethics approval and appropriate patient consent. The inclusion criteria were: male patients older than 18 years, with single short recurrent not-obliterating urethral stricture (<2 cm). The exclusion criteria were: patients not willing to consent, multiple strictures and those not deemed suitable for endoscopic management. Failure was defined as need for further interventions. Preoperative workup included history, examination, retrograde urethrogram (RGU), voiding cystourethrogram (VCUG), urine culture, renal function tests, AUA score, IIEF, PROM. Plastic surgery team performs liposuction to extract 50 mls of fat from the patient's abdominal wall. 50ml fat-SVF was obtained using a Goog Manufacturing Practice collagenase (Celaseâ, Cytori Therapeutics, San Diego, USA) according to a standard protocol. SVF was diluted in 5 ml saline solution for the injection. A cystoscopy was performed and the stricture evaluated, a glide wire was placed and an urethrotomy performed at 6 o'clock position in bulbar urethra. Gide wire was left in situ. The SVF solution was injected at the site of the stricture and on either side of the stricture. A 12 Fr urinary catheter was placed. The urinary catheter was removed after 24 hrs. Follow up was of 3.5 months.
RESULTS: Two patients were included in the study. The main characteristics are reported in table 1. No local or systemic side effects or complications were recorded. No recurrence of urethral stricture was detected in both patients after 3.5 months. Table 1 CONCLUSIONS: This is the first study to demonstrate a successful autologous SVF transplantation in male urethral stricture after DVIU. Further studies are necessary to confirm the efficacy of SVF in preventing urethral stricture recurrence.
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Sofia Karkampouna, Bern, Switzerland; Federico la Manna, Leiden, Netherlands; Eugenio Zoni, Bern, Switzerland; Lijkele Beimers, Peter Kloen, Amsterdam, Netherlands; Antoinette Wetterwald, Joel Grosjean, Irena Klima, Marco G. Cecchini, Martin Spahn, George N. Thalmann, Marianna Kruithof-de Julio*, Bern, Switzerland INTRODUCTION AND OBJECTIVES: Prostate cancer (PCa)-associated mortality results from metastasis to bone and resistance to androgen deprivation or cytotoxic therapy. Despite early detection of primary PCa, advanced castration resistant prostate cancer (CRPC) and bone metastases (BM) are detected in 10% of patients already at the time of initial diagnosis. The majority of recurrences might be due to therapy resistant cancer cells with stem cell-like properties (cancer stem cell-like, CSC-like). CSC-like cells are highly tumorigenic and metastatic, however, current treatments target the differentiated tumor bulk cells. Our aim is to determine whether CSC-like cells from metastases tissues are responsive to the standard compounds used for the treatment of the primary tumor type. METHODS: To model metastatic CSC-like cells we have generated organoids (here termed as »canceroids«) from patientderived biopsies and established patient-derived xenografts (PDXs). Cytotoxic compounds and androgen inhibitors are being tested on the canceroids from different BM or LN tissues in order to determine whether agents targeting the primary tumor are effective in the metastases. Viability assays and light sheet microscopy imaging are used.
RESULTS: We have successfully derived canceroids from bulk tumor tissues, in particular; primary PCa, bone metastasis from PCa tissue (BM-PCa), established metastatic PDX models LAPC9 and BM18 and lymph node (LN) metastasis from PCa (LAPC4) PDX models. Canceroids maintain key features of the original tumor; the known luminal phenotype of BM18 is evidently maintained in the BM18 canceroids, based on positive cytokeratin (CK)18 and absent CK5 expression. LAPC4 organoids contain CK5 and CK18 cells, in line with the mixed basal and luminal phenotype. BM18 and LAPC9 canceroids are maintained in presence and absence of dihydrotestosterone in order to determine whether they adjust to androgen (in)dependent status of growth. Ongoing studies involve growth response of BM-PCa, BM18, LAPC4 and LAPC9 canceroids to chemotherapeutics (cabacitaxel, docetaxel) and hormone inhibitors (abiraterone, enzalutamide).
CONCLUSIONS: Identification of the oncogenic properties of metastatic CSC-like (sub)populations has both prognostic and therapeutic applications. Establishment of CSC-derived organoids from BM tissue is the first step towards routine derivation from metastasis or primary PCa tissues as a potential platform for personalized drug compound evaluation.
Source of Funding: Swiss National Funds
MP41-11 A PILOT CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL WITH RIBAVIRIN IN PATIENTS WITH PROGRESSIVE CASTRATION-RESISTANT PROSTATE CANCER TARGETING STEM-CELL RELATED GENE NETWORK.
Takeo Kosaka*, Takahiro Maeda, Hirohiko Nagata, Shunsuke Yoshimine, Hiroshi Hongo, Toshiaki Shinojima, Mototsugu Oya, Tokyo, Japan INTRODUCTION AND OBJECTIVES: We previously reported a novel cell reprogramming approach, termed drug efficacy reprogramming, as a new model for identifying candidate antitumor drugs targeting the cancer stemness-related gene network, and identified ribavirin as a candidate drug for overcoming docetaxel-resistant castration-resistant prostate cancer (CRPC). This nonrandomized, open-labeled pilot clinical study explored the safety and efficacy of ribavirin, an antiviral drug, in combination with docetaxel in patients with progressive CRPC.
METHODS: In this clinical study, patients received intravenous docetaxel 60e70 mg/mm2 on day 1 of 3e6-week cycles plus ribavirin 600 mg twice daily. The primary endpoint was safety, prostate-specific antigen (PSA) response and objective response rate. Secondary endpoints included health-related quality of life and overall survival. Patients with progressive CRPC based on PSA and/or radiographic criteria, performance status (PS) 0e1, and normal renal and hepatic function were eligible. Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e539
